Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs TransMedics Group Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while TransMedics Group Inc trades at $74.59 (market cap $2.58B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 55.2× TransMedics Group Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BBVA | TMDX | |
|---|---|---|
Market Cap | $142.30B | $2.58B |
Sector | Financials | Technology |
52-Week High | $26.14 | $150.42 |
52-Week Low | $14.73 | $61.99 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $2.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
